Associated tags: Therapy, Drug discovery, Patient, SAN, Heron, Pharmaceutical industry, Webcast, Vomiting, Pharming, Video game
Locations: , HERON, MASSACHUSETTS, CALIFORNIA, MA, BOSTON
PFS,
FDA,
Elective surgery,
Partnership,
VAN,
Foot,
Cross-link,
Physician,
Heron,
Ankle,
Adjustment,
Human,
Therapy,
SAN,
Pharmaceutical industry Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® promotional efforts in the first quarter of 2024.
Key Points:
- Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® promotional efforts in the first quarter of 2024.
- Gross Margin improved to 76% for the quarter, up from 43% for the same period last year.
- Heron to host its first ever Investor Day event on Wednesday, May 15, 2024 in New York, New York.
- SAN DIEGO, May 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2024 and highlighted recent corporate updates.
Retrieved on:
Wednesday, April 24, 2024
SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m.
Key Points:
- SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m.
- ET to report first quarter 2024 financial results and discuss recent business highlights.
- The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com .
- An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET.
Key Points:
- SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET.
- The presentations will also include updates on several ongoing initiatives in the Acute Care franchise to expand reach and adoption.
- The event will include a live webcast which will be archived and available for replay after the event.
- Please visit the "Investors" section of the Company website at Investor Resources - Heron Therapeutics (herontx.com) to register for the webcast and for additional information on the event.
SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference.
Key Points:
- SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference.
- The conference is being held in a virtual format, April 8-11, 2024.
- A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section.
ZYNRELEF Net Product Sales: Net Product Sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2023 were $5.6 million and $17.7 million, respectively, which increased from $3.9 million and $10.2 million, respectively, for the same periods in 2022.
Key Points:
- ZYNRELEF Net Product Sales: Net Product Sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2023 were $5.6 million and $17.7 million, respectively, which increased from $3.9 million and $10.2 million, respectively, for the same periods in 2022.
- APONVIE® Net Product Sales: Net Product Sales of APONVIE for the three and twelve months ended December 31, 2023 were $0.5 million and $1.4 million, respectively, with no sales in the comparable prior year periods.
- CINVANTI® Net Product Sales: Net Product Sales of CINVANTI (aprepitant) injectable emulsion for the three and twelve months ended December 31, 2023 were $24.3 million and $94.9 million, respectively, which increased from $23.1 million and $87.3 million, respectively, for the same periods in 2022.
- SUSTOL® Net Product Sales: Net Product Sales of SUSTOL (granisetron) extended-release injection for the three and twelve months ended December 31, 2023 were $3.8 million and $13.0 million, respectively, which increased from $3.0 million and $10.2 million, respectively, for the same periods in 2022.
Retrieved on:
Wednesday, February 28, 2024
ET to report fourth quarter and full year 2023 financial results and discuss recent business highlights.
Key Points:
- ET to report fourth quarter and full year 2023 financial results and discuss recent business highlights.
- The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally.
- The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com .
- An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
Retrieved on:
Wednesday, January 24, 2024
System,
Death,
Allergy,
Heron,
Patient,
Vitamin,
Naproxen,
Elective surgery,
SAN,
Health,
Partnership,
Foot,
Gastrointestinal bleeding,
Ibuprofen,
Vomiting,
Anemia,
Ankle,
Stroke,
Heart failure,
Medicine,
Nonsteroidal anti-inflammatory drug,
Patient satisfaction,
Cartilage,
Risk,
Meloxicam,
Pain,
VAN,
Cross-link,
Food,
Constipation,
Pregnancy,
NDA,
Anesthetic,
Aspirin,
Tears,
FDA,
Ulcer,
Liver,
Boxed warning,
New Drug Application,
Headache,
Bupivacaine,
Human,
Blood,
Pharmaceutical industry SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
Key Points:
- ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
- This expanded indication for ZYNRELEF will now cover an estimated 13 million procedures annually, an estimated increase of 86% over prior indicated procedures.
- To obtain this labeling expansion, Heron successfully conducted studies for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
- The most common side effects of ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache.
Partnership,
Heron,
Meloxicam,
SAN,
Therapy,
Spine,
Growth,
Bupivacaine,
Patient,
Cross-link,
VAN,
Nursing The partnership will launch in several phases, initially at a regional level, followed by an expanded national rollout.
Key Points:
- The partnership will launch in several phases, initially at a regional level, followed by an expanded national rollout.
- In total, approximately 650 representatives will be added to Heron's sales network over the next year.
- CrossLink will be the lead partner in the United States to expand ZYNRELEF promotion for orthopedic indications.
- "CrossLink has a proven track record of success in building relationships, providing superior service to healthcare providers and improving patient outcomes.
Retrieved on:
Tuesday, November 14, 2023
Sale,
Fresenius (company),
EBITDA,
Webcast,
New product development,
SAN,
Markman,
Therapy,
Bupivacaine,
Investment,
Depreciation,
Patient,
VAN,
Meloxicam,
New Drug Application,
Aprepitant,
Growth,
PDUFA,
Heron,
Patent,
Optimism,
Pharmaceutical industry,
Risk management,
Beauty salon,
Cryptocurrency I am delighted to offer this quarterly update on our expectations for the fourth quarter and to unveil our 2024 guidance.
Key Points:
- I am delighted to offer this quarterly update on our expectations for the fourth quarter and to unveil our 2024 guidance.
- Guidance for 2023 and 2024:
The Company is updating guidance for the remainder of 2023 and establishing guidance for the full year 2024 that reflects the growth potential of the product portfolio and the output of our continual operational improvements.
- Full-year 2023 net product sales guidance for the oncology care franchise is being increased to a range of $104 million to $106 million from a prior range of $99 million to $103 million.
- EBITDA (excluding stock compensation) expected in the range of ($10 million) to ($6 million) in the fourth quarter of 2023.
Retrieved on:
Tuesday, November 7, 2023
ET to report third quarter 2023 financial results and discuss recent business highlights.
Key Points:
- ET to report third quarter 2023 financial results and discuss recent business highlights.
- The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally.
- The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com .
- An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
